Atara Biotherap (ATRA)

$8.34 -1.59 (-16.01%)
Market Cap 70.99M
Revenue (ttm) 120.77M
Net Income (ttm) 32.69M
EPS (ttm) N/A
PE Ratio 1.65
Forward PE 25.75
Profit Margin 27.07%
Debt to Equity Ratio 0.00
Volume 3,002,900
Avg Vol 1,839,738
Day's Range N/A - N/A
Shares Out 8.51M
Stochastic %K 48%
Beta -0.30
Analysts Sell
Price Target $9.33

Company Profile

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to tar...

Industry: Biotechnology
Sector: Healthcare
Phone: 805 623 4211
Address:
1280 Rancho Conejo Blvd, Thousand Oaks, United States
_BottomPlays
_BottomPlays May. 9 at 8:23 PM
Make sure to keep eyes on ticker AMS📈 for next week! It does not get better than this in small caps. AMS has the recipe to see a massive run! ✅ No current dilution ✅ Volume picking up ✅ Momentum building ✅ Clean chart setup ✅ Major contract locked through 2033 ✅ Improving fundamentals $CCHH $ATRA $CABR $INBX ..ww119
0 · Reply
Joby099
Joby099 May. 9 at 6:14 PM
$ATRA
0 · Reply
topstockalerts
topstockalerts May. 9 at 4:06 PM
After Hours Top Gainers PT2 $INO $ATRA $RXT $CABR $DAIC
0 · Reply
TonySuprano
TonySuprano May. 9 at 2:00 PM
$ATRA
0 · Reply
Joby099
Joby099 May. 9 at 3:00 AM
$ATRA
0 · Reply
topstockalerts
topstockalerts May. 9 at 2:00 AM
After Hours Top Gainers PT2 $INO $ATRA $RXT $CABR $DAIC
0 · Reply
luckysupernova
luckysupernova May. 9 at 1:51 AM
$ATRA bulls stepped up ah, awesome stuff. Already put of my position.
0 · Reply
username_is_taken
username_is_taken May. 9 at 12:47 AM
$ATRA oh goodness ppl shorting over the weekend must be shitting themselves after seeing it run back to mid 9s with no indication of slowing down. Dilution may already be over.
0 · Reply
username_is_taken
username_is_taken May. 9 at 12:45 AM
$ATRA heheheheh
0 · Reply
Tazdoc88
Tazdoc88 May. 9 at 12:03 AM
$ATRA Get ready for it to 🚀 on Monda
0 · Reply
Latest News on ATRA
Atara Biotherapeutics upgraded to Buy from Hold at Canaccord

2026-05-08T08:50:11.000Z - 1 day ago

Atara Biotherapeutics upgraded to Buy from Hold at Canaccord

Atara Biotherapeutics trading halted, volatility trading pause

2026-05-07T18:17:49.000Z - 2 days ago

Atara Biotherapeutics trading halted, volatility trading pause

Atara Biotherapeutics jumps 70%, or $3.60, to $8.75

2026-05-07T18:16:36.000Z - 2 days ago

Atara Biotherapeutics jumps 70%, or $3.60, to $8.75

Atara Biotherapeutics trading resumes

2026-05-07T18:14:10.000Z - 2 days ago

Atara Biotherapeutics trading resumes

Atara says PFP had productive meeting with FDA

2026-05-07T13:09:48.000Z - 2 days ago

Atara says PFP had productive meeting with FDA

Why Is Atara Biotherapeutics Stock (ATRA) Up Today?

2026-05-07T13:00:26.000Z - 2 days ago

Why Is Atara Biotherapeutics Stock (ATRA) Up Today?

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

May 7, 2026, 8:05 AM EDT - 2 days ago

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA

Apr 28, 2026, 9:00 AM EDT - 11 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA

ATRA Stockholders Have Rights - If You Lost Money Investing in Atara Biotherapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Apr 16, 2026, 6:10 PM EDT - 23 days ago

ATRA Stockholders Have Rights - If You Lost Money Investing in Atara Biotherapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff Role

Apr 7, 2026, 6:00 PM EDT - 4 weeks ago

ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff Role

Atara Biotherapeutics files to sell 400K shares of common stock for holders

2026-03-17T20:20:37.000Z - 7 weeks ago

Atara Biotherapeutics files to sell 400K shares of common stock for holders

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

Mar 16, 2026, 4:05 PM EDT - 7 weeks ago

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

Atara provides update on tabelecleucel biologics license application

2026-03-12T12:45:52.000Z - 2 months ago

Atara provides update on tabelecleucel biologics license application

Atara Biotherapeutics partner submits Type A meeting request to FDA

2026-03-03T13:10:42.000Z - 2 months ago

Atara Biotherapeutics partner submits Type A meeting request to FDA

Atara Biotherapeutics amends HealthCare Royalty purchase, sale agreement

2026-02-23T13:15:10.000Z - 2 months ago

Atara Biotherapeutics amends HealthCare Royalty purchase, sale agreement

Atara Biotherapeutics Provides a Business Update

Feb 23, 2026, 8:00 AM EST - 2 months ago

Atara Biotherapeutics Provides a Business Update

Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier)

2026-01-13T18:40:59.000Z - 4 months ago

Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier)

FDA says unable to approve Atara Biotherapeutics Ebvallo BLA in present form

2026-01-12T13:37:46.000Z - 4 months ago

FDA says unable to approve Atara Biotherapeutics Ebvallo BLA in present form

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

Jan 12, 2026, 8:00 AM EST - 4 months ago

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears

2026-01-08T15:34:07.000Z - 4 months ago

Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears

Atara Biotherapeutics price target raised to $25 from $17 at Canaccord

2025-12-19T11:31:07.000Z - 5 months ago

Atara Biotherapeutics price target raised to $25 from $17 at Canaccord

Atara Biotherapeutics price target raised to $18 from $16 at Mizuho

2025-11-20T19:45:19.000Z - 6 months ago

Atara Biotherapeutics price target raised to $18 from $16 at Mizuho

Atara Biotherapeutics price target raised to $140 from $131 at Mizuho

2025-11-20T19:40:14.000Z - 6 months ago

Atara Biotherapeutics price target raised to $140 from $131 at Mizuho

Atara Biotherapeutics reports Q3 EPS (32c), consensus (67c)

2025-11-12T14:15:44.000Z - 6 months ago

Atara Biotherapeutics reports Q3 EPS (32c), consensus (67c)

Atara Biotherapeutics reduces workforce by 29%

2025-11-12T14:15:32.000Z - 6 months ago

Atara Biotherapeutics reduces workforce by 29%

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

Nov 12, 2025, 9:00 AM EST - 6 months ago

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Nov 3, 2025, 9:00 AM EST - 6 months ago

Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Atara Biotherapeutics Announces Changes to Its Board of Directors

Sep 3, 2025, 6:00 PM EDT - 8 months ago

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Aug 11, 2025, 4:01 PM EDT - 9 months ago

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Jul 24, 2025, 8:57 AM EDT - 10 months ago

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Jul 24, 2025, 8:00 AM EDT - 10 months ago

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

Jul 15, 2025, 8:00 AM EDT - 10 months ago

Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

Jul 14, 2025, 8:00 AM EDT - 10 months ago

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

Atara Biotherapeutics Transcript: AGM 2025

Jun 10, 2025, 12:00 PM EDT - 11 months ago

Atara Biotherapeutics Transcript: AGM 2025

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

May 16, 2025, 8:50 PM EDT - 1 year ago

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

May 15, 2025, 8:35 AM EDT - 1 year ago

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

Atara Biotherapeutics Announces Pricing of $16 Million Offering

May 15, 2025, 8:30 AM EDT - 1 year ago

Atara Biotherapeutics Announces Pricing of $16 Million Offering

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

May 5, 2025, 5:06 PM EDT - 1 year ago

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Mar 7, 2025, 4:01 PM EST - 1 year ago

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Mar 1, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Feb 15, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Feb 14, 2025, 8:11 AM EST - 1 year ago

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation

Feb 11, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Feb 10, 2025, 7:00 AM EST - 1 year ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Feb 9, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 4:01 PM EST - 1 year ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect

Feb 7, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect

Feb 6, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation

Feb 5, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation

Feb 4, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud

Feb 3, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 3, 2025, 7:00 AM EST - 1 year ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation

Jan 31, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation

Jan 30, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out

Jan 29, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out

_BottomPlays
_BottomPlays May. 9 at 8:23 PM
Make sure to keep eyes on ticker AMS📈 for next week! It does not get better than this in small caps. AMS has the recipe to see a massive run! ✅ No current dilution ✅ Volume picking up ✅ Momentum building ✅ Clean chart setup ✅ Major contract locked through 2033 ✅ Improving fundamentals $CCHH $ATRA $CABR $INBX ..ww119
0 · Reply
Joby099
Joby099 May. 9 at 6:14 PM
$ATRA
0 · Reply
topstockalerts
topstockalerts May. 9 at 4:06 PM
After Hours Top Gainers PT2 $INO $ATRA $RXT $CABR $DAIC
0 · Reply
TonySuprano
TonySuprano May. 9 at 2:00 PM
$ATRA
0 · Reply
Joby099
Joby099 May. 9 at 3:00 AM
$ATRA
0 · Reply
topstockalerts
topstockalerts May. 9 at 2:00 AM
After Hours Top Gainers PT2 $INO $ATRA $RXT $CABR $DAIC
0 · Reply
luckysupernova
luckysupernova May. 9 at 1:51 AM
$ATRA bulls stepped up ah, awesome stuff. Already put of my position.
0 · Reply
username_is_taken
username_is_taken May. 9 at 12:47 AM
$ATRA oh goodness ppl shorting over the weekend must be shitting themselves after seeing it run back to mid 9s with no indication of slowing down. Dilution may already be over.
0 · Reply
username_is_taken
username_is_taken May. 9 at 12:45 AM
$ATRA heheheheh
0 · Reply
Tazdoc88
Tazdoc88 May. 9 at 12:03 AM
$ATRA Get ready for it to 🚀 on Monda
0 · Reply
MB6288
MB6288 May. 8 at 11:40 PM
$ATRA PS, Canaccord Genuity is a complete fucking joke. Their upgrade means dogshit.
0 · Reply
MB6288
MB6288 May. 8 at 11:38 PM
$ATRA OK, last post. Good luck everyone. I’m short btw. Here’s the deal. 1) Go to http://www.finviz.com. 2) Scroll down to the Financials section. 3) Read the Balance Sheet, particularly Cash & Short Term Investments and Short Term Debt. 4) read the Income Statement, particularly Total Revenue and Net Income. Finally, get the fuck out or short the living shit out of this one. It’s beyond dead!!!! Thank you for your attention to this matter.
0 · Reply
xHiddenGems
xHiddenGems May. 8 at 11:10 PM
AMS 🚨 is the next parabolic runner for next week. Don't say I didn' tell you. Look at AMS go, I think it will pull the biggest run! Don't end up chasing it, be early bulls, I believe AMS has the look! $AREB $ONEG $SOBR $ATRA ..1211
1 · Reply
xHiddenGems
xHiddenGems May. 8 at 11:00 PM
If you missed out on plays like $GDC $RXT $ATRA $TRAW no worries because... AMS 🚨 is the next parabolic runner for next week. Look at AMS go, I think it will pull the biggest run! Don't end up chasing it, be early bulls, I believe AMS has the look!
0 · Reply
Tazdoc88
Tazdoc88 May. 8 at 9:27 PM
$ATRA
0 · Reply
Pharoh42
Pharoh42 May. 8 at 8:37 PM
$ATRA I am back to avg down my $14 avg
0 · Reply
Ftruck
Ftruck May. 8 at 7:41 PM
$ATRA I am shorting this to $5.94
1 · Reply
StockSenseiTrendTraders
StockSenseiTrendTraders May. 8 at 7:31 PM
$AIIO Strong end to the week with this one. Only trade made today. $ATRA $MNDR $GLE $MASK Some other good winners from this week. Live on zoom every trading day!
0 · Reply
Bonanza2252003
Bonanza2252003 May. 8 at 7:25 PM
$ATRA First . Don’t ever take analysts seriously and second the company is broke and needs to raise money asap , IE : major dilution .
0 · Reply
StockSupra
StockSupra May. 8 at 7:04 PM
$ATRA why down if they adjusted the target price from $6 to $13
0 · Reply
Joby099
Joby099 May. 8 at 6:42 PM
$ATRA
0 · Reply
Hart4Charts
Hart4Charts May. 8 at 6:41 PM
$ATRA thin biotech tape, one volume push changes the setup fast
0 · Reply